An over-expression of this gene has been previously observed in human cervical cancer, invasive breast carcinoma, human astrocytoma, human pituitary adenoma, and canine osteosarcoma [31], [34], [35], [36], [10]; in addition, the relative expression of serum circulating CCNB2 mRNA in human cancer patients was significantly higher than in normal controls and benign disease group, and significantly correlated with cancer stage and metastasis status. This evidence concerns the gene CCNB2 and astrocytoma (excluding glioblastoma).